Advertisement

European Journal of Nuclear Medicine

, Volume 17, Issue 5, pp 264–268 | Cite as

Whole-body distribution of iodine 123 metaiodobenzylguanid1ne in hypertrophic cardiomyopathy: significance of its washout from the heart

  • Junichi Taki
  • Kenichi Nakajima
  • Hisashi Bunko
  • Masami Simizu
  • Akira Muramori
  • Kinichi Hisada
Original Article

Abstract

Whole-body distribution of iodine 123 metaiodobenzylguanidine (123I-mIBG) was evaluated in 27 patients with hypertrophic cardiomyopathy (HCM). At 1 and 4 h after injection, anterior and posterior whole body images were obtained with a dual-headed, camera computer system. Patients were classified into three groups based on the septal wall thickness as determined by echocardiography: group 1 consisted of 7 patients with ≤ 15 mm septal thickness, group 2 included 12 patients with 16–19 mm septal thickness, and group 3 included 6 patients with ≽ 20 mm septal thickness. Although the myocardial mIBG uptakes at 1 h were similar among these groups (1.84% ± 0.19%, 1.95% ± 0.38%, 1.98% ± 0.57%, respectively; NS), mIBG washout from the heart in group 3 was faster than in groups 1 and 2 (31.5% ± 13.0% vs. 15.8% ± 11.0% (group 1,P < 0.05), 17.6% ± 7.3% (group 2,P < 0.01)). There was a significant positive correlation between mIBG washout from the heart and septal thickness, with correlation coefficientr=0.52 (P < 0.01). The liver, lung, parotid gland, spleen and skeletal muscle showed similar mIBG uptake and washout among the three groups. We conclude from these data that mIBG washout from the heart in HCM was faster in patients with severe hypertrophy than in patients with mild to moderate hypertrophy, and hence it may be a useful parameter for evaluating the severity of altered adrenergic innervation and activities.

Key words

Iodine 123 metaiodobenzylguanidine Myocardial scintigraphy Hypertrophic cardiomyopathy Sympathetic nervous system 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baulieu JL, Guilloteau D, Delisle MJ, Perdrisot R, Gradet P, Delepine N, Baulieu F, Doupond JL, Talbot JN, Coutris G, Calmettes C, French Medullary Cancer Study Group (1987) Radioiodinated metaiodobenzylguanidine (mIBG) uptake in medullary thyroid cancer (MTC). A French cooperative study. Cancer 60:2189–2194Google Scholar
  2. Ciro E, Nichols PF III, Maron BJ (1983) Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Circulation 67:1227–1233Google Scholar
  3. Dae MW, O'Connell JW, Botvinik EH, Ahearn T, Yee E, Huberty JP, Mori H, Chin MC, Hattner RS, Herre JM, Munoz L (1989 a) Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 79:634–644Google Scholar
  4. Dae MW, O'Connell WC, Munoz L, Newman D, Botvinik E, Chin M (1989 b) Scintigraphic assessment of myocardial nerve development with mIBG washout maps. J Nucl Med 30:810 (abstr)Google Scholar
  5. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR (1989) Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 30:1182–1191Google Scholar
  6. Goodwin JF (1982) The frontiers of cardiomyopathy. Br Heart J 48:1–18Google Scholar
  7. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, Ugolini V, Akers MS, Hansen C, Buja LM, Parkey RW, Willersn JT (1988) Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 78:1192–1199Google Scholar
  8. Kimming B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, Winkel K (1984) Scintigraphy of a neuroblastoma with I-131 metaiodobenzylguanidine. J Nucl Med 25:773–775Google Scholar
  9. Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, Shinohara S (1986) Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 27:84–89Google Scholar
  10. Paton DM (1980) Neuronal transport of noradrenaline and dopamine. Pharmacology 21:85–92Google Scholar
  11. Perloff JK (1981) Pathogenesis of hypertrophic cardiomyopathy: hypotheses and speculations. Am Heart J 101:219–226Google Scholar
  12. Rabinovitch MA, Rose CP, Rouleau JL, Chartrand C, Wieland DM, Lepanto L, Legault F, Suissa S, Rosenthall L, Burgess JH (1987) Metaiodobenzylguanidine [131-I] scintigraphy detects impaired myocardial sympathetic neuronal transport function of canine mechanical-overloaded heart failure. Circ Res 61:797–804Google Scholar
  13. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585Google Scholar
  14. Shen SW, Sisson JC, Shulkin B, Fung A, Shapiro B, Meyers L, Ackerman R, Mallett S (1986) I-123-metaiodobenzylguanidine (1-123-mIBG) as an index of neuron integrity following myocardial infarction. J Nucl Med 27:949 (abstr)Google Scholar
  15. Sisson JC, Sherman WP, Manger TJ, Tobes MC, Jacques S Jr (1987 a) Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 28:1620–1624Google Scholar
  16. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, Glowniak JV, Sherman P, Beierwaltes WH (1987 b) Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625–1636Google Scholar
  17. Sisson JC, Wieland DM, Jacques S Jr, Sherman P, Fisher S, Mallette S, Meyers L, Mangner TJ (1987c) Radiolabeled metaiodobenzylguanidine and the adrenergic neurons of salivary glands. Am J Physiol Imaging 2:1–9Google Scholar
  18. Tobes MC, Jaques S, Wieland DM, Sisson JC (1985) Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26:897–907Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Junichi Taki
    • 1
  • Kenichi Nakajima
    • 1
  • Hisashi Bunko
    • 1
  • Masami Simizu
    • 2
  • Akira Muramori
    • 1
  • Kinichi Hisada
    • 1
  1. 1.Department of Nuclear MedicineKanazawa University, School of MedicineKanazawaJapan
  2. 2.The Second Department of Internal MedicineKanazawa University, School of MedicineKanazawaJapan

Personalised recommendations